Anaesthesia and Intensive Care最新文献

We report the case of successful elective percutaneous transtracheal oxygen insufflation in a patient with high-grade laryngeal stenosis, requiring repeat surgical laryngeal dilation, in the setting of multiple previous failed attempts at intubation and ventilation. This case report highlights the role of this technique as an initial management plan to provide general anaesthesia in a safe and simple way to patients with a known difficult airway. We also describe the use of an intravenous extension kit which allowed end-tidal carbon dioxide to be measured during transtracheal oxygen insufflation.

Ketamine is an N-methyl-d-aspartate receptor antagonist approved for use in anaesthesia, with analgesic properties. Despite publication of numerous trials and expert guidelines on its use for pain management, administration of ketamine as part of multimodal perioperative analgesia remains 'off-label'. We conducted an online, prospective survey of ANZCA Fellows, exploring current prescribing practices of intravenous ketamine for perioperative analgesia. We surveyed 2000 Fellows and received 806 responses. The factors mostly likely to influence their administration of perioperative ketamine included pre-existing chronic pain, and heavy or multiple opioid use by patients preoperatively. Amongst respondents, less senior anaesthetists and those working in public hospitals were more likely to administer intraoperative ketamine. The surgical procedures most likely to result in ketamine administration intraoperatively were open pelvic/abdominal, thoracic and major spinal surgery, where ketamine administration was likely practice for the majority of respondents, with typical loading doses that ranged widely. The commonest choices of intraoperative loading dose were between 0.2 mg kg^-1 and 0.6 mg kg^-1. The commonest choice of intraoperative and postoperative infusion rate was in the range of 0.1-0.2 mg kg^-1 h^-1. Postoperative ketamine infusion was most commonly prescribed as third-line or rescue analgesia. The majority of respondents thought it either 'likely' or 'very likely' ketamine would reduce postoperative chronic pain after thoracic surgery, but not in other surgical categories. Our findings suggest that off-label perioperative administration of ketamine at analgesic dose ranges is routine or common practice in major surgery for a majority of specialist anaesthetists in Australia and New Zealand.

Early mobilisation following elective total hip arthroplasty (THA) facilitates quicker rehabilitation, and reduces complications and hospital length of stay. Reasons for delayed mobilisation are multifactorial, but the most common cause is orthostatic intolerance. Midodrine, an oral alpha-1 agonist, is used off-label for perioperative hypotension. However, there are few randomised trials assessing its use in the perioperative setting to improve patient outcomes. The aim of the study was to determine whether midodrine improves early mobilisation following primary THA, and whether this relates to reduced orthostatic intolerance. This prospective, triple-blinded, multicentre study involved 42 patients randomised to either placebo or 20 mg midodrine, 2 h before physiotherapy, on Day 1 postoperatively. The inclusion criteria were adults undergoing elective unilateral THA under spinal anaesthesia. The primary endpoint was the ability to walk 5 m with physiotherapists. Secondary endpoints included the incidence of orthostatic intolerance and hypotension. A preplanned interim analysis showed no statistical difference in ability to mobilise 5 m (78.26% vs 78.95%, P = 1.0). There was no statistically significant difference in the incidence of orthostatic intolerance between the groups 17.4% vs 31.6% (P = 0.45). Pre-emptive use of midodrine did not improve patient mobilisation the morning after elective primary THA and had no significant effect on the incidence of orthostatic hypotension.

Volatile anaesthetic agents such as sevoflurane contribute to greenhouse gas emissions, and selecting low fresh gas flows on anaesthetic machines minimises their waste. Facilitating improvements in sevoflurane use requires the education, motivation, and standardised evaluation of anaesthetists. There is currently no standard of practice related to the efficiency of anaesthetic gas delivery per case. We conducted a multi-component study termed 'Low With The Flow' (LWTF) to directly address these requirements by educating and motivating anaesthetists to reduce fresh gas flow and thereby sevoflurane use. We introduced a novel metric, the 'volatile efficiency ratio' (VER), able to be calculated on Draeger Primus™, the Draeger Atlan™ family and Draeger Perseus A500™ machines, to audit sevoflurane use in a case-by-case fashion, and assess whether the intervention could achieve a set VER target. The LWTF intervention significantly improved the efficiency of sevoflurane delivery (VER 0.46 pre-intervention (n = 518) versus VER 0.57 post-intervention (n = 531), 95% confidence interval 0.092 to 0.129, P < 0.0001) resulting in a calculated average of 1.3 kg carbon dioxide equivalent emissions reduction and approximately AUD 3.50 saving per case. Consequently, the financial and environmental outcomes from sevoflurane delivery were considerably reduced. Our LWTF intervention provides a valuable model for other anaesthetic departments to investigate and address the global environmental and financial burdens related to their volatile anaesthetic use. For anaesthetists using anaesthesia machines that do not facilitate calculation of VER, an approach using components of our LWTF intervention may still reduce the environmental and financial impacts associated with administration of volatile anaesthesia.